FCM
Farallon Capital Management’s CRISPR Therapeutics CRSP Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-530,000
| Closed | -$28.6M | – | 162 |
|
|
2024
Q2 | $28.6M | Buy |
+530,000
| New | +$28.6M | 0.12% | 61 |
|
|
2020
Q3 | – | Sell |
-150,000
| Closed | -$11M | – | 123 |
|
|
2020
Q2 | $11M | Sell |
150,000
-200,000
| -57% | -$14.7M | 0.09% | 98 |
|
|
2020
Q1 | $14.8M | Hold |
350,000
| – | – | 0.13% | 71 |
|
|
2019
Q4 | $21.3M | Sell |
350,000
-210,367
| -38% | -$12.8M | 0.14% | 80 |
|
|
2019
Q3 | $23M | Buy |
560,367
+60,367
| +12% | +$2.47M | 0.17% | 69 |
|
|
2019
Q2 | $23.6M | Sell |
500,000
-225,000
| -31% | -$10.6M | 0.15% | 69 |
|
|
2019
Q1 | $25.9M | Sell |
725,000
-525,000
| -42% | -$18.8M | 0.19% | 62 |
|
|
2018
Q4 | $35.7M | Buy |
1,250,000
+231,406
| +23% | +$6.61M | 0.26% | 52 |
|
|
2018
Q3 | $45.2M | Buy |
1,018,594
+157,894
| +18% | +$7M | 0.27% | 50 |
|
|
2018
Q2 | $50.6M | Buy |
860,700
+215,700
| +33% | +$12.7M | 0.31% | 50 |
|
|
2018
Q1 | $29.5M | Sell |
645,000
-213,602
| -25% | -$9.76M | 0.2% | 58 |
|
|
2017
Q4 | $20.2M | Buy |
+858,602
| New | +$20.2M | 0.16% | 53 |
|